Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
| Revenue (TTM) | $14.73B |
| Gross Profit (TTM) | $6.00B |
| EBITDA | $4.24B |
| Operating Margin | 12.60% |
| Return on Equity | -4.21% |
| Return on Assets | 2.66% |
| Revenue/Share (TTM) | $12.75 |
| Book Value | $11.91 |
| Price-to-Book | 1.59 |
| Price-to-Sales (TTM) | 1.55 |
| EV/Revenue | 2.266 |
| EV/EBITDA | 12.10 |
| Quarterly Earnings Growth (YoY) | -70.60% |
| Quarterly Revenue Growth (YoY) | -0.30% |
| Shares Outstanding | $1.15B |
| Float | $1.14B |
| % Insiders | 0.32% |
| % Institutions | 93.01% |
Volatility is currently expanding
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Viatris Inc. (VTRS) Q3 2026 Earnings Call Transcript
VTRS beats Q3 earnings estimates on stronger margins and raises 2026 earnings guidance, despite revenue miss and persistent supply constraints.
Viatris (VTRS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.67 per share a year ago.
Delivers Total Revenues of $3.75 Billion, U.S. GAAP Net Loss of $325 Million and Adjusted EBITDA of $1.20 Billion Receives Regulatory Approval for RYZUMVI® for Presbyopia in the U.S. and WAKIX® in Japan Returns Approximately $717 Million of Capital to Shareholders Year to Date, Including Through Share Repurchases Advances Innovative Medicines Strategy with Planned Acquisition of Pacira BioSciences, Expected to Close by the End of November Raises 2026 Financial Guidance Midpoints for All Metrics [1] PITTSBURGH, Nov. 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced its third-quarter 2026 financial results. Executive Commentary "Our third-quarter results reflect strong execution and reinforce our confidence in the growth trajectory of our business," said Scott A.
Evaluate the expected performance of Viatris (VTRS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
VTRS heads into Q3 earnings with new product growth, regional sales trends and supply challenges shaping its outlook.
The third-quarter 2026 earnings season is revealing a familiar healthcare divide: demand is holding up, but not every business is turning that demand into stronger profits. Laboratories are ordering more equipment, cancer testing continues to expand, and animal health innovation is attracting customers.
PITTSBURGH, Oct. 30, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that Peach Purchaser Sub Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, has commenced a tender offer to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Pacira BioSciences, Inc. ("Pacira") (Nasdaq: PCRX), for $36.50 per Share, in cash, net of applicable withholding taxes and without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated Oct. 30, 2026 (as it may be amended or supplemented from time to time, the "Offer to Purchase"), and the accompanying Letter of Transmittal (the "Letter of Transmittal" and, together with the Offer to Purchase and other related materials, as they may be amended or supplemented from time to time, the "Offer"). The Offer is being made pursuant to the Agreement and Plan of Merger, dated Oct. 8, 2026, by and among Viatris, Purchaser and Pacira (as it may be amended or supplemented from time to time, the "Merger Agreement").
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on VTRS and any ticker you trade — then tracks every position and per-strategy win rate.
